We use cookies to ensure the best user experience. By using the page, you accept the usage of cookies.
Read more
OK
Skip to Content
FI
SV
EN
Close navigation
Front page
For public
Open or close sub-menu
Databases and registers
Open or close sub-menu
Development and HTA
Open or close sub-menu
Marketing Authorisations
Open or close sub-menu
Pharmaceutical safety and information
Open or close sub-menu
Pharmacies
Open or close sub-menu
Supervision
Open or close sub-menu
Veterinary
Open or close sub-menu
About us
Open or close sub-menu
Open or close main menu
Contact Information
FI
SV
EN
SearchBar
Search field
Search
fimea.fi
For public
Safety of medicines
Adverse reactions
Inverted black triangle
Counterfeit medicines
Product defects
Drug interactions
Correct use of medicines
Package leaflet
Pain relievers
Medicines and dietary supplements
How to dispose of medicines
Generic products and generic substitution
Medicines and pregnancy
Medicines for children
Developing better medicines for children
Medication of the elderly
Travellers' medicines
Influenza
Influenza vaccinations
Antiviral medication
Pandemic
Vaccines
Internet trade in medicines
Reliability of pharmaceutical information
Databases and registers
Meds75+
Database
SmPCs and PLs
Human medicinal products
What does the SPC contain?
Search instructions for the SPC
Veterinary medicinal products
What does the SPC contain?
Search instructions for the SPC
Herbal medicinal products
What does the SPC contain?
Search instructions for the SPC
Package leaflets for medicine
Package leaflets for veterinary medicines
Package leaflets for herbal medicinal products
FimeaWeb
Consumption
Self-medication products
Basic register
Plasma-derived products with marketing authorisation
Substitutable medicinal products
Textfile for databases
Criteria used in compiling the list
Consumption information
Development and HTA
Assessment of pharmacotherapies (HTA)
Assessment of hospital-only medicinal products
Nordic collaboration (FINOSE)
Assessment reports (in Finnish)
Research
Research Network for Rational Pharmacotherapy (RATTI)
Medicines information
Medicines Information Network
High-quality medicines information
Interprofessional network
Marketing Authorisations
Marketing authorisation application
Finland as a Reference Member State in the decentralised procedure (DCP)
Finland as a Reference Member State in the Mutual Recognition / Repeat Use Procedure (MRP/RUP)
Changing of Reference Member State duties to Finland
Finland as a rapporteur in the centralised marketing authorisation procedure (CP)
Granted and cancelled marketing authorisations
Pending marketing authorisation applications
Biological Medicinal Products
Orphan drugs
Paediatric medicines
European Pharmacopoeia
Active substance names and standard terms
Renewals and variation applications
Renewals
Variation applications
Changes to labelling
Transferring a marketing authorisation to a new holder
Article 5 classification requests for variation applications
OTC application
Product Information
Summary of product characteristics
Package leaflet
Package labelling
Text templates
Braille and package leaflets for the visually impaired
Trade names of medicinal products
Strength
Translating influenza vaccines in Finland
Electronic marketing authorisation submissions
What's new
Instructions for electronic marketing authorisation submissions
Special characteristics of the electronic marketing authorisation process for veterinary medicines
Cancelling a marketing authorisation or registration and sunset clause
Cancelling a marketing authorisation or registration
Expiration of marketing authorisations and registrations (sunset clause)
Sunset clause - concepts
Sunset clause exemption
List of expired marketing authorisations and registrations
Introduction to market
Parallel import
Herbal remedies and medicinal products
Herbal medicinal products
Traditional herbal medicinal products
Homeopathic and anthroposophic preparations
Innovation Office
Informal Regulatory Guidance
Scientific Advice
Interchangeable medicinal products
Safety features
Other permits
Exemption
Frequently asked questions - marketing authorisations
Summary of Product Characteristics is to be available also in Swedish
Local representative
Pharmaceutical safety and information
Pharmaceutical safety
Reporting adverse reactions
Biological medicinal products
Biosimilars
Biosimilars in Finland
Regulation on Medicinal Products for Paediatric Use
Paediatric Committee
Paediatric Investigation Plan
Coordination and communication
Rewards and incentives
Symbol in the labels of medicinal products
Pharmacies
Pharmacy licences
How to apply for a pharmacy licence
Supervision Committee
Pharmacy tax
Special permits
How to apply for a special permit
Temporary special permit products
Manufacturing medicinal products
Schengen certificates
PIC/S GMP Guide
Dose-dispensing
Supervision
Pharmacovigilance
ICSR reporting to the EudraVigilance system
Product defects
Summaries of risk management plans
Fimea's Instructions to the National Implementation of the Directive 2010/84/EU
Product-specific risk minimisation material
Clinical Drug Trials
Notification of a clinical trial - EudraCT
Serious Unexpected Adverse Reactions in Clinical Trials (SUSARs)
Advertising of medicinal products
Classification
Principles of classification
Classification application
List of medicines
After classification
Private imports of medicinal products
Pharmaceutical industry
Licenses
Local pharmaceutical wholesale license holders
Registered brokers of medicinal products
Good Laboratory Practice (GLP)
Mandatory reserve supplies
Reports on quantities to be stocked as mandatory reserve supplies
List of products to be stocked as mandatory reserve supplies
Application for exemption to maintain lower stock levels
Special arrangements for fulfilment of the obligation to maintain mandatory reserve supplies
Establishments
Supervising blood services
Supervising tissue establishments
Supervision of organ activity
Certificates of a Pharmaceutical Product (CPP)
Applying for an export certificate
Narcotics control
Additional information to be submitted with narcotics licence applications
Batch-specific control
GMP certificates
Laboratory of Fimea
National and international collaboration
Legislation
International and EU legislation
European Pharmacopoeia
National pharmacopoeia documents
To users of the Pharmacopoeia
CEP Procedure
International Non-proprietary Names for Pharmaceutical Substances (INN)
National laws
Administrative regulations
Normative guidelines
Other guidelines
Veterinary
Marketing authorisation procedures
Special permits for compassionate use
Applying for special permit
FAQ
A Questions and answers on how to fill in the form
B Questions and answers regarding the technical aspects of permit application
C Questions and answers regarding the decision and the processing of the application
D Other questions and answers
Lists of veterinary medicinal products
Adverse effects
Consumption of veterinary antimicrobials
The European Surveillance of Veterinary Antimicrobial Consumption ESVAC
Clinical trials on veterinary medicinal products
Immunological products
Withdrawal period and MRL
What is a withdrawal period?
MRL
Horses as food-producing animals
Private import
About us
Contact us
Change of address
Ordering of publications
Copyright
Contact
Personnel
Forms
Organisation
Strategy
Our goals
Strategic framework
International representation
Fimea committees
What's new
News archive
Brexit
EU Presidency 2019
Publications
Fees
Estimated processing times
Frequently asked questions
Clinical drug trials
Generic medicines
Invoicing
Marketing authorisations
Summary of Product Characteristics is to be available also in Swedish
Narcotics control
New EudraVigilance -system
Open positions
Open data
fimea.fi
Personnel
Personnel
Suomeksi
⁄
På svenska
ID card portlet
Räsänen Kaarina
Telephone
+358295223654
Visiting address
Fimea-HELSINKI, PL 55
Postal address
Fimea
Post office
00034
Return
fimea.fi
Personnel
Print
Sulje ohje
